There are currently 1572 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
FT576 in Subjects With Multiple Myeloma
NCT05182073
Recruiting
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Texas Oncology-Medical City Dallas, Dallas, Texas
Conditions: Multiple Myeloma, Myeloma
Register for Updates
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
NCT04620239
Recruiting
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase w... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter
Register for Updates
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
NCT04372433
Recruiting
To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: University of Texas Southwestern, Simmons Comprehensive Cancer Center (104), Dallas, Texas
Conditions: AML With Monocytic Differentiation, CMML
Register for Updates
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344
Recruiting
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/13/2024
Locations: GSK Investigational Site, Dallas, Texas
Conditions: Nonalcoholic Fatty Liver Disease
Register for Updates
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
NCT04903873
Recruiting
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Mary Crowley Center, Dallas, Texas
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Renal Cell Cancer Metastatic, Renal Cell Carcinoma, Prostate Cancer
Register for Updates
SegwayPD: The Effect of Sensory-augmented Postural Training Using Segway on Motor and Cognitive Function in Individuals With Parkinson's Disease
NCT05982730
Recruiting
The purpose of this study is to examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control in individuals with PD. This project is a proof-of-concept study to assess the effectiveness of postural training using Segway, which serves a platform to provide augmented and continuous proprioceptive and visuospatial information during postural training.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
03/13/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Parkinson Disease
Register for Updates
Spinal Cord Injury Model Systems (SCIMS) - Education Module
NCT06003686
Recruiting
The purpose of this study is to find out if receiving education regarding increased risks of cardiometabolic disease helps subjects understand these risks and how these risks participants' health.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/13/2024
Locations: Baylor Scott & White Institute for Research, Dallas, Texas
Conditions: Spinal Cord Injuries, Obesity, Cardiometabolic Syndrome
Register for Updates
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
NCT03929601
Recruiting
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.
Gender:
All
Ages:
Between 8 years and 45 years
Trial Updated:
03/13/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Type 1 Diabetes Mellitus
Register for Updates
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Harold C. Simmons Comprehensive Cancer Center - UT Southwestern Medical Center, Dallas, Texas
Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
Register for Updates
COMPASSION S3 Post-Approval Study
NCT04860765
Recruiting
This study will monitor device performance and outcomes of the SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted surgical valve in the pulmonic position with a clinical indication for intervention.
Gender:
All
Ages:
All
Trial Updated:
03/12/2024
Locations: Children's Health Dallas, Dallas, Texas
Conditions: Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Pulmonary Valve; Obstruction
Register for Updates
ALTERRA Post-Approval Study
NCT05378386
Recruiting
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Gender:
All
Ages:
All
Trial Updated:
03/12/2024
Locations: Medical City Dallas, Dallas, Texas
Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Register for Updates
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
NCT05584202
Recruiting
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
Gender:
All
Ages:
Between 2 months and 6 months
Trial Updated:
03/12/2024
Locations: Cedar Health Research - Dedicated Research Facility, Dallas, Texas
Conditions: SARS-CoV-2
Register for Updates